Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Amicus Therapeutics Inc

+ Add to Watchlist

AM6:GR

7.514 EUR 0.044 0.59%

As of 02:10:31 ET on 03/04/2015.

Company Profile for Amicus Therapeutics Inc (AM6)

Amicus Therapeutics, Inc. is a biopharmaceutical company that develops orally-administered, small molecule drugs to treat human genetic diseases. The drugs, called pharmacological chaperones, are being developed to treat Fabray, Gaucher, and Pompe disease.

Contact Information

Amicus Therapeutics Inc

6 Cedar Brook Drive
Cranbury, NJ 08512
United States
Phone: 1-609-662-2000

Key Executives for Amicus Therapeutics Inc (AM6)

John F CrowleyChairman/CEOBradley L CampbellPresident/COO
William D Baird III "Chip"Chief Financial OfficerJay BarthChief Medical Ofcr
Hung DoSenior VP:Discovery BiologyPeter M MacalusoVP/Secretary/Counsel
Daphne QuimiVP:Finance/ControllerJohn R KirkVP:Regulatory Affairs
Ken ValenzanoVP:PharmacologyKenneth W PeistVP:Intellectual Property
Enrique DiloneVP:Technical OperationsJeffrey P CastelliVP:Program
Julie YuVP:Clinical OperationsJayne GershkowitzVP:Patient Advocacy
Sara PellegrinoDirector:Investor Relations

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil